NCT06081712 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TNP-2198 Capsules in Asymptomatic Participants With Helicobacter Pylori Infection | Biotech Hunter

Enrollment

48

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

July 15, 2021

Study Completion Date

July 15, 2021

Conditions

Helicobacter Pylori Infection

Interventions

DRUG

TNP-2198

TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.

DRUG

TNP-2198 Placebo

TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.

Trial Locations (1)

Unknown

The First Hospital of Jilin University, Changchun